Table 4. Clinical and laboratory characteristics in CPP patients with each polymorphism.
| No. | SNP | Time of diagnosis, yr | SMR | LH, mIU/mL | FSH, mIU/mL | Peak LH/FSH ratio | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| CA | BA | Basal | Peak | Basal | Peak | |||||
| 1 | c.-123C>T | - | 7.8 | 9.2 | 2.5 | 0.5 | 11.8 | 2.6 | 16.8 | 0.77 |
| 2 | c.24A/G | Synonymous | 7.9 | 9.6 | 2.4 | 0.4 | 10.8 | 2.8 | 15.4 | 0.77 |
| 3 | c.245-34G>A | - | 8.1 | 9.8 | 2.8 | 0.8 | 15.4 | 3.7 | 15.9 | 1.07 |
| 4 | c.505+42T>G | - | 8.1 | 9.8 | 2.7 | 0.6 | 13.9 | 3.0 | 15.4 | 1.01 |
| 5 | c.738+64G>T | - | 8.2 | 9.8 | 2.5 | 0.7 | 14.5 | 3.0 | 15.3 | 1.07 |
| 6 | c.1091T>A | p.Leu364His | 7.9 | 9.5 | 2.4 | 0.3 | 11.9 | 2.3 | 13.9 | 0.94 |
| 7 | c.*120C>G | - | 8.1 | 9.7 | 2.5 | 0.6 | 13.7 | 3.0 | 15.5 | 0.99 |
The positions of the polymorphisms are defined according to NM_032551.4. Data are shown as the mean value.
CPP = central precocious puberty, SNP = single-nucleotide polymorphism, LH = luteinizing hormone, FSH = follicle-stimulating hormone, CA = chronological age, BA = bone age, SMR = sexual maturity rating.